Clinical Trials

Date: 2017-08-24

Type of information: Treatment of the first patient

phase: 1-2

Announcement: treatment of the first patient

Company: MeiraGTx (USA - NY)

Product: AAV2/5-hRKp.RPGR

Action mechanism: gene therapy

Disease: X-Linked retinitis pigmentosa (XLRP)

Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases

Country:

Trial details:

Latest news:

• • On August 24, 2017, MeiraGTx announced  the first patient in its clinical study for X-Linked retinitis pigmentosa (XLRP) was treated at Moorfields Eye Hospital in London. This clinical study is the first-in-man Phase I/II dose escalation study of AAV2/5-hRKp.RPGR, MeiraGTx’s AAV-mediated gene therapy for XLRP caused by mutations in the RP GTPase regulator gene (RPGR).

 

Is general: Yes